Related Experiment Video

Updated: Nov 27, 2025

Long-Term Continuous Measurement of Renal Blood Flow in Conscious Rats
05:09

Long-Term Continuous Measurement of Renal Blood Flow in Conscious Rats

Published on: February 8, 2022

2.9K

Dapagliflozin Does Not Affect Short-Term Blood Pressure Variability in Patients With Type 2 Diabetes Mellitus

Eirini Papadopoulou1,2, Marieta P Theodorakopoulou1, Charalampos Loutradis1

  • 1Department of Nephrology, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece.

American Journal of Hypertension
|December 5, 2020
PubMed
Abstract

Insights

Dapagliflozin did not alter short-term blood pressure variability (BPV) in patients with type-2 diabetes mellitus (T2DM). This study found no significant changes in BPV indexes with dapagliflozin compared to placebo over 12 weeks.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Increased blood pressure variability (BPV) is linked to higher mortality in type-2 diabetes mellitus (T2DM).
  • Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are known to reduce cardiovascular events in T2DM patients.

Purpose of the Study:

  • To investigate the impact of dapagliflozin on short-term BPV in patients with T2DM.
  • To determine if SGLT-2 inhibition influences BP fluctuations in this population.

Main Methods:

  • Secondary analysis of a 12-week randomized, placebo-controlled trial involving 85 T2DM patients.
  • 24-hour ambulatory BP monitoring was performed at baseline and study-end.
  • Multiple BPV indices, including SD, wSD, and ARV, were calculated for different time periods.

Main Results:

  • Dapagliflozin did not significantly alter any measured 24-hour, daytime, or nighttime BPV indices compared to placebo.
  • No significant differences in BPV index changes were observed between the dapagliflozin and placebo groups.
  • Brachial BP was reduced by dapagliflozin, but BPV remained unchanged.

Conclusions:

  • Dapagliflozin demonstrated no effect on short-term blood pressure variability in T2DM patients.
  • This is the first study to report on the effects of an SGLT-2 inhibitor on BPV in T2DM.
  • Further research may be needed to explore long-term BPV effects or effects in different patient subgroups.
Keywords:
SGLT-2 inhibitorambulatory blood pressure monitoringblood pressureblood pressure variabilitydapagliflozindiabetes mellitushypertension

More Related Videos

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

542
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.3K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
386
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
474
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
438
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
480
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.9K
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
1.6K